Medicenna Therapeutics (MDNA) Short Interest Ratio & Short Volume

Short interest is the volume of Medicenna Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 109,400 shares of MDNA short. 0.21% of Medicenna Therapeutics' shares are currently sold short. Learn More on Medicenna Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.21% of Medicenna Therapeutics' floating shares are currently sold short.

Medicenna Therapeutics saw a drop in short interest during the month of October. As of October 15th, there was short interest totaling 109,400 shares, a drop of 33.4% from the previous total of 164,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Medicenna Therapeutics currently has issued a total of 69,637,000 shares. Some of Medicenna Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Medicenna Therapeutics currently has a public float of 53,170,000 shares.

0.21% of Medicenna Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Medicenna Therapeutics: Eagle Pharmaceuticals, Inc. (0.46%), Marinus Pharmaceuticals, Inc. (3.95%), Allakos Inc. (0.37%), Cara Therapeutics, Inc. (1.74%), NanoViricides, Inc. (1.62%), 23andMe Holding Co. (11.90%), GlycoMimetics, Inc. (2.90%), AEON Biopharma, Inc. (5.67%), Orgenesis Inc. (0.13%), China Pharma Holdings, Inc. (2.27%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.82 billion), T-Mobile US, Inc. ($3.69 billion), Occidental Petroleum Corporation ($2.90 billion), TC Energy Corporation ($2.74 billion), Tractor Supply Company ($2.28 billion), Rivian Automotive, Inc. ($1.92 billion), Moderna, Inc. ($1.77 billion), Celsius Holdings Inc. ($1.72 billion), Coinbase Global, Inc. ($1.66 billion), and Royal Caribbean Cruises Ltd. ($1.65 billion). View all of the most shorted stocks.

Short selling MDNA is an investing strategy that aims to generate trading profit from Medicenna Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Medicenna Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MDNA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MDNA, twice per month. The most recent reporting period available is October, 15 2023.